Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody

Circulation

Volumn 121, Issue 1, 2010, Pages 80-90

  Arslan, Fatih ^a,b   Smeets, Mirjam B ^a   O'Neill, Luke A J ^c   Keogh, Brian ^d   McGuirk, Peter ^d   Timmers, Leo ^a   Tersteeg, Claudia ^a   Hoefer, Imo E ^a   Doevendans, Pieter A ^a,b   Pasterkamp, Gerard ^a,b   De Kleijn, Dominique P V ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Immune system; Inflammation; Myocardial infarction; Reperfusion; Toll like receptors

Indexed keywords

CASPASE 3; CASPASE 7; CYTOKINE RECEPTOR ANTAGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; OPN 301; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; HEMATOPOIESIS; LEUKOCYTES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDITIS; MYOCARDIUM; SIGNAL TRANSDUCTION; SYSTOLE; TOLL-LIKE RECEPTOR 2;

EID: 74549178528     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.880187     Document Type: Article

References (26)

1. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
3. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des. 2008;14:1205-1216.
4. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res. 2004;95:125-134.
5. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83:345-352.
6. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58:88-111.
7. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylpred-nisolone in patients with myocardial infarction. Circulation. 1976; 53(suppl):I-204-I-206.
8. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest. 1973;52:599-607.
9. Spath JA Jr, Lane DL, Lefer AM. Protective action of methylprednisolone on the myocardium during experimental myocardial ischemia in the cat. Circ Res. 1974;35:44-51.
10. Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296:301-305.
11. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000;275:11058-11063.
12. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
13. Brikos C, O'Neill LA. Signalling of toll-like receptors. Handb Exp Pharmacol. 2008;183:21-50.
14. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ, Tacheuchi O, Akira S, Mann DL. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292:H503-H509.
15. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2007;27:1064-1071.
16. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res. 2006;72:384-393.
17. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108: 2905-2910.
18. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, de Kleijn DP. Toll-like receptor 4 mediates mal-adaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102:257-264.
19. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960;70:68-78.
20. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481.
21. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adeno-sine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775-1780.
22. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88:581-609.
23. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009;296:H1-H12.
24. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, Chao W. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 2008;295: H1311-H1318.
25. Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL. p38 MAPK inhibition reduces myocardial reper-fusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res. 2002;53: 414-4022.
26. Klune JR, Billiar TR, Tsung A. HMGB1 preconditioning: therapeutic application for a danger signal? J Leukoc Biol. 2008;83: 558-563.